News & Updates

Faces of Lung Cancer Report
Reflection of COVID-19. The annual report is now available!
Read More

 

Health Canada Approves Tagrisso for NSCLC

More good news for lung cancer patients: Health Canada approves Tagrisso for treatment of NSCLC

LCC Welcomes New President Dr Paul Wheatley-Price

Lung Cancer Canada would like to welcome Dr Paul Wheatley-Price as our new President.  Dr Wheatley-Price was voted in at the Annual General Meeting held on June 15, 2016.

LCC Summer Studentship Grant Program

The Lung Cancer Canada Summer Studentship Grant Program provides support for highly qualified applicants in all areas of lung cancer health research at all post-secondary stages to add to their experience by engaging in health research in Canada.  A number of $5,000 (CDN) grants are available as a one-time funding opportunity.

pCODR invites stakeholders’ input on Pembrolizumab (Keytruda) for NSCLC

Please contact Lung Cancer Canada (info@lungcancercanada.ca) if you are a patient or caregiver of a patient on Keytruda.  Your experience with this treatment is a crucial part of the decision process!

Renowned Public Health Physician's Battle Against Disease Was Personal

Tenacious Dr. Terry-Nan Tannenbaum, renowned public health physician, fought super-bugs, SARS, tuberculosis and HIV in others for decades until her fight became personal when she was diagnosed with terminal lung cancer.

Dr. Juergens' Interview with CTV News

Dr. Rosalyn Juergens' interview with Pauline Chan at CTV News on the promising results from the drug Opdivo (Nivolomab).

pCODR Releases Initial Recommendation of Opdivo

pCODR releases initial recommendation of Opdivo (nivolumab) for metastatic NSCLC (both squamous and non-squamous); on or after chemotherapy. No test required.  

This is a great news for NSCLC patients!  We hope to see more like this for other types of lung cancer.

Ontario’s Two-Tiered Cancer System is a Problem That Requires Immediate Treatment

Your experience with cancer care in Ontario depends greatly on the type of cancer you have, the kind of treatment you are prescribed, your age and family income – all of which can make or break the timeliness and quality of care you receive. Ontario’s two-tiered cancer drug system includes widely different drug reimbursement models and variable safety standards and support for patients who take their cancer medications at home versus in a hospital or cancer clinic.

Lung Cancer Screening Receives a Positive Recommendation

Some good news for Canada's deadliest cancer:
The Canadian Task Force on Preventive Health Care now recommends screening using low-dose CT scans in high-risk adults aged 55-74 years who are current or former smokers with a smoking history of at least 30 pack-years, defined as the average number of packs smoked daily multiplied by the number of years of smoking. This is big step in the fight against lung cancer! [Canadian Cancer Statistics, 2015]

Highlights of the Canadian Lung Cancer Conference 2016

In February 2016, 350 cancer specialists from across Canada gathered in Vancouver for the 16th annual Canadian Lung Cancer Conference chaired by Dr. Barb Melosky and Dr. Cheryl Ho. Participants included medical oncologists, radiation oncologists, surgeons, pathologists, oncology nurses as well as members of the pharmaceutical industry, who came together with a common interest in improving the care of patients with lung cancer in Canada.

Displaying results 81-90 (of 101)
 |<  <  2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 - 11  >  >|